Aims and scope
Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed, online journal of the Society for Immunotherapy of Cancer (SITC). The journal publishes articles on all aspects of tumor immunology and cancer immunotherapy and, in doing so, aims to enrich communication and advance scientific understanding among the many stakeholders in this rapidly evolving field. Topics of interest range widely across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.
JITC publishes high quality original research articles, literature reviews, position papers and practice guidelines, and case reports; invited commentaries may also be commissioned by the journal. Together, these articles make JITC the leading forum for research in tumor immunology and cancer immunotherapy.
All articles published by Journal for ImmunoTherapy of Cancer are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Journal for ImmunoTherapy of Cancer you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Journal for ImmunoTherapy of Cancer therefore levies an article-processing charge of £1540.00/$2410.00/€1965.00 for each article accepted for publication.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BioMed Central provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
Articles published in Journal for ImmunoTherapy of Cancer are included in:
- Directory of Open Access Journals (DOAJ)
- PubMed Central
- Science Citation Index Expanded (SCIE)
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
Peer review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help Editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.
Journal for ImmunoTherapy of Cancer operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.
The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
The journal aims to provide authors with a first decision (accepted/rejected/revisions needed) within six weeks.
Authors will be able to check the progress of their manuscript at any time by logging into the journal's submission system Editorial Manager.
All manuscripts submitted to Journal for ImmunoTherapy of Cancer should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in Journal for ImmunoTherapy of Cancer
Articles in Journal for ImmunoTherapy of Cancer should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Journal for ImmunoTherapy of Cancer [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Journal for ImmunoTherapy of Cancer 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.
Why publish your article in Journal for ImmunoTherapy of Cancer
Journal for ImmunoTherapy of Cancer's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Journal for ImmunoTherapy of Cancer offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Journal for ImmunoTherapy of Cancer gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Journal for ImmunoTherapy of Cancer are included in article alerts and regular email updates. Some may be highlighted on Journal for ImmunoTherapy of Cancer’s pages and on the BioMed Central homepage.
In addition, articles published in Journal for ImmunoTherapy of Cancer may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Journal for ImmunoTherapy of Cancer. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in Journal for ImmunoTherapy of Cancer you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.